Fosun Pharma raises $512 million, while Dynasty Reit cancels IPO

The market remains challenging for new listings and both deals attract modest demand from international investors, with Fosun forced to reallocate shares to retail investors to make up for the lack of institutional interest.

To continue reading, please login or register for free

Print Edition

FinanceAsia Print Edition